A Phase 1 Study of PMN-310 for Alzheimer's Disease
Phase of Trial: Phase I
Latest Information Update: 20 Nov 2018
At a glance
- Drugs PMN 310 (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions
- 20 Nov 2018 According to a ProMIS Neurosciences media release, this trial will use an innovative clinical trial design using emerging biomarkers that may indicate early signs of efficacy.The company expects to generate initial clinical results by end of 2020.
- 12 Jun 2018 According to a ProMIS Neurosciences media release, the molecule PMN310 is anticipated to enter phase 1 trial in second half of 2019.
- 13 Sep 2017 According to a ProMIS Neurosciences media release, the molecule PMN310 is on track for initiation of this trial in 2019.